In Los Angeles, California, the Pfizer-BioNTech COVID Vaccine was 73 percent effective in protecting children between the ages of 6 months and 4 years. These figures were announced by Pfizer. The US Food and Drug Administration approved the vaccine for emergency use on June 17 for children ages 6 months to 4 years.
Study Participants Received Three Doses of Either the Pfizer-BioNTech Vaccine or A Placebo
Citing the results announced by the two companies, Xinhua news agency reported that the vaccine efficacy in children aged 6 months to 4 years in the first Kovid-19 infection was 73.2 percent.
Ugur Sahin, CEO and co-founder of BioNTech, said, “While these results confirm that three 3-ug doses of our COVID-19 vaccine provide high levels of protection for young children, at a time when Omicron The Ba.2 strain is highly prevalent.”
